The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells.
AGEs
IL-8
RAGE
breast cancer
cancer-associated fibroblasts
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
04 08 2022
04 08 2022
Historique:
received:
01
07
2022
revised:
29
07
2022
accepted:
02
08
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Advanced glycation end products (AGEs) and the cognate receptor, named RAGE, are involved in metabolic disorders characterized by hyperglycemia, type 2 diabetes mellitus (T2DM) and obesity. Moreover, the AGEs/RAGE transduction pathway prompts a dysfunctional interaction between breast cancer cells and tumor stroma toward the acquisition of malignant features. However, the action of the AGEs/RAGE axis in the main players of the tumor microenvironment, named breast cancer-associated fibroblasts (CAFs), remains to be fully explored. In the present study, by chemokine array, we first assessed that interleukin-8 (IL-8) is the most up-regulated pro-inflammatory chemokine upon AGEs/RAGE activation in primary CAFs, obtained from breast tumors. Thereafter, we ascertained that the AGEs/RAGE signaling promotes a network cascade in CAFs, leading to the c-Fos-dependent regulation of IL-8. Next, using a conditioned medium from AGEs-exposed CAFs, we determined that IL-8/CXCR1/2 paracrine activation induces the acquisition of migratory and invasive features in MDA-MB-231 breast cancer cells. Altogether, our data provide new insights on the involvement of IL-8 in the AGEs/RAGE transduction pathway among the intricate connections linking breast cancer cells to the surrounding stroma. Hence, our findings may pave the way for further investigations to define the role of IL-8 as useful target for the better management of breast cancer patients exhibiting metabolic disorders.
Identifiants
pubmed: 35954247
pii: cells11152402
doi: 10.3390/cells11152402
pmc: PMC9368521
pii:
doi:
Substances chimiques
Interleukin-8
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Breast Cancer. 2019 Aug;19(4):e522-e533
pubmed: 31029558
Cell. 2018 Feb 8;172(4):841-856.e16
pubmed: 29395328
Front Oncol. 2021 Mar 25;11:629666
pubmed: 33842335
Biochim Biophys Acta. 2007 Apr;1768(4):794-807
pubmed: 17188232
Cells. 2021 Sep 06;10(9):
pubmed: 34571976
Expert Opin Ther Targets. 2013 Nov;17(11):1235-41
pubmed: 24032691
Endocrinology. 2020 Jan 1;161(1):
pubmed: 31638645
Cancer Res. 2011 Aug 1;71(15):5296-306
pubmed: 21653678
Oncol Rep. 2019 Jun;41(6):3508-3516
pubmed: 31002348
Blood Rev. 2016 May;30(3):213-21
pubmed: 26723842
Exp Mol Med. 2021 Feb;53(2):168-188
pubmed: 33568752
Front Cell Dev Biol. 2020 Dec 08;8:608412
pubmed: 33364239
Biochem Biophys Res Commun. 1987 Dec 16;149(2):755-61
pubmed: 3322281
Breast Cancer Res. 2013;15(4):210
pubmed: 24041156
Breast Cancer Res Treat. 2019 Feb;173(3):559-571
pubmed: 30368741
Tumour Biol. 2015 Mar;36(3):1385-94
pubmed: 25680413
Oncogene. 2017 Mar;36(11):1559-1572
pubmed: 27669433
Med Oncol. 2015 Dec;32(12):258
pubmed: 26519257
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
J Carcinog. 2011;10:40
pubmed: 22368515
Biochim Biophys Acta. 2016 Dec;1862(12):2244-2252
pubmed: 27166197
J Cell Physiol. 2021 Oct;236(10):7014-7032
pubmed: 33748944
Front Oncol. 2021 Feb 02;10:615375
pubmed: 33604295
Cells. 2019 Mar 07;8(3):
pubmed: 30866584
PLoS One. 2017 Jan 11;12(1):e0170084
pubmed: 28076434
Int J Mol Sci. 2021 Apr 29;22(9):
pubmed: 33946884
Cancers (Basel). 2021 Jun 23;13(13):
pubmed: 34201840
Sci Rep. 2014 Aug 01;4:5911
pubmed: 25081383
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
Br J Cancer. 2021 Jan;124(1):27-36
pubmed: 33239677
Oncotarget. 2017 Feb 28;8(9):14428-14442
pubmed: 28129639
Oncoimmunology. 2017 Aug 8;6(11):e1359450
pubmed: 29147624
Nucleic Acids Res. 2005 Nov 10;33(20):e175
pubmed: 16284200
Horm Cancer. 2018 Oct;9(5):295-325
pubmed: 29987748
Nat Rev Cancer. 2006 May;6(5):392-401
pubmed: 16572188
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Osteoarthritis Cartilage. 2015 Nov;23(11):1946-54
pubmed: 26521741
Cells. 2020 Jun 02;9(6):
pubmed: 32498358
Cancer Res. 2015 Mar 15;75(6):974-85
pubmed: 25572331
Clin Cancer Res. 2004 Nov 1;10(21):7157-62
pubmed: 15534087
J Exp Clin Cancer Res. 2020 Aug 10;39(1):153
pubmed: 32778144
Front Cell Dev Biol. 2019 Apr 24;7:60
pubmed: 31106200
Cells. 2022 Jun 09;11(12):
pubmed: 35741001
Eur J Pharmacol. 2020 Nov 5;886:173453
pubmed: 32777211
Br J Cancer. 2012 Oct 23;107(9):1608-17
pubmed: 22996614
Int J Cancer. 2004 Apr 20;109(4):507-15
pubmed: 14991571
Endocr Relat Cancer. 2012 Nov 19;19(6):793-803
pubmed: 23035011
Cancers (Basel). 2021 Feb 04;13(4):
pubmed: 33557316
Cancer Res. 2002 Oct 1;62(19):5571-9
pubmed: 12359770
Pharmacol Ther. 2021 Mar;219:107692
pubmed: 32980444
J Am Diet Assoc. 2004 Aug;104(8):1287-91
pubmed: 15281050
Am J Pathol. 2001 Feb;158(2):639-46
pubmed: 11159200
Cells. 2021 Jan 08;10(1):
pubmed: 33429846
Endocr Relat Cancer. 2007 Dec;14(4):1039-52
pubmed: 18045955
J Biol Chem. 2005 Mar 11;280(10):9706-18
pubmed: 15615716
Cancer Cell Int. 2021 Jul 5;21(1):351
pubmed: 34225729
Cell Tissue Res. 2016 Sep;365(3):675-89
pubmed: 27506216
J Leukoc Biol. 2002 Nov;72(5):847-55
pubmed: 12429706
J Biol Chem. 1992 Jul 25;267(21):14998-5004
pubmed: 1378843
Oncotarget. 2017 Jul 21;8(36):60210-60222
pubmed: 28947965
Oncogene. 2013 Apr 4;32(14):1821-30
pubmed: 22614006
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9233-7
pubmed: 3480540
Cell Death Dis. 2017 Jul 13;8(7):e2932
pubmed: 28703802
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cells. 2022 Apr 23;11(9):
pubmed: 35563739
Int J Biol Sci. 2017 Nov 1;13(11):1387-1397
pubmed: 29209143
Cell Signal. 2014 Jul;26(7):1466-75
pubmed: 24662263
Mol Cancer. 2019 Dec 3;18(1):175
pubmed: 31796058
Mol Cell. 2012 Aug 24;47(4):570-84
pubmed: 22819326
Nutrients. 2017 Apr 14;9(4):
pubmed: 28420091
Science. 1991 Sep 13;253(5025):1278-80
pubmed: 1840701
Stem Cell Res Ther. 2015 May 01;6:87
pubmed: 25928089
Adv Exp Med Biol. 2021;1302:25-39
pubmed: 34286439
Panminerva Med. 2015 Sep;57(3):101-8
pubmed: 25971328
Breast Cancer Res Treat. 2020 Jun;181(3):561-570
pubmed: 32361849
Sci Rep. 2016 Apr 13;6:24354
pubmed: 27072893
Cancers (Basel). 2021 Aug 03;13(15):
pubmed: 34359821
Electrophoresis. 2010 Oct;31(21):3573-9
pubmed: 20967768
Oncol Res Treat. 2016;39(10):622-628
pubmed: 27710974
Cell Commun Signal. 2009 May 08;7:12
pubmed: 19426472
Front Cell Dev Biol. 2020 Sep 17;8:586176
pubmed: 33043018
Expert Rev Clin Immunol. 2014 May;10(5):593-619
pubmed: 24678812
Diabetes Res Clin Pract. 2005 Jan;67(1):3-21
pubmed: 15620429
Science. 1991 Sep 13;253(5025):1280-3
pubmed: 1891716
Cell Death Dis. 2015 Jul 30;6:e1834
pubmed: 26225773
Cells. 2021 Nov 12;10(11):
pubmed: 34831367
PLoS One. 2011;6(8):e22865
pubmed: 21826213
Signal Transduct Target Ther. 2020 Mar 12;5(1):28
pubmed: 32296047
BMC Med Genomics. 2008 Sep 21;1:42
pubmed: 18803878
Anal Biochem. 2015 Sep 1;484:40-50
pubmed: 25983236
Biomolecules. 2015 Mar 16;5(1):194-222
pubmed: 25786107
Oncogene. 2003 Jan 16;22(2):256-65
pubmed: 12527894
Front Oncol. 2019 Feb 06;9:40
pubmed: 30788286
Mol Cell Biochem. 2021 Mar;476(3):1555-1573
pubmed: 33398664
Int J Mol Med. 2012 Apr;29(4):613-8
pubmed: 22293957
Biomolecules. 2015 Jul 01;5(3):1386-98
pubmed: 26140537
Genes Dis. 2018 May 12;5(2):77-106
pubmed: 30258937
Int J Cancer. 2007 Nov 1;121(9):1949-1957
pubmed: 17621625
Diabetologia. 2020 Jan;63(1):75-84
pubmed: 31511931
Oncotarget. 2017 Dec 05;8(70):115709-115717
pubmed: 29383194
Curr Breast Cancer Rep. 2018 Mar;10(1):14-27
pubmed: 30662586
Mediators Inflamm. 2012;2012:504952
pubmed: 22685373
Expert Opin Ther Targets. 2020 Jun;24(6):559-572
pubmed: 32249708
J Leukoc Biol. 2009 Sep;86(3):529-43
pubmed: 19564575
BMC Cancer. 2018 Feb 27;18(1):231
pubmed: 29486738
Cancer Res. 2013 Jun 1;73(11):3470-80
pubmed: 23633491
Cancer Res. 2014 Aug 1;74(15):4053-64
pubmed: 24894716
Cancer Lett. 2019 Jul 10;454:37-43
pubmed: 30978440
Breast Cancer Res Treat. 2012 Oct;135(3):737-47
pubmed: 22923236
Redox Biol. 2014 Jan 09;2:411-29
pubmed: 24624331
Cells. 2022 Apr 27;11(9):
pubmed: 35563777
Signal Transduct Target Ther. 2021 Jul 12;6(1):263
pubmed: 34248142
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
Cancer Lett. 2005 Jan 10;217(1):73-86
pubmed: 15596298
Int J Cancer. 2017 Jun 15;140(12):2657-2666
pubmed: 28268252
Clin Cancer Res. 2017 Sep 15;23(18):5358-5365
pubmed: 28539464
Annu Rev Immunol. 2000;18:217-42
pubmed: 10837058
Oncotarget. 2015 Dec 22;6(41):43375-94
pubmed: 26517518
Cancer Treat Rev. 2017 Nov;60:24-31
pubmed: 28866366
Diabetes Metab J. 2018 Jun;42(3):188-195
pubmed: 29885110
Cells. 2022 Apr 12;11(8):
pubmed: 35455991
Mol Cancer Res. 2017 Jan;15(1):3-14
pubmed: 27678171
Front Oncol. 2014 Mar 27;4:62
pubmed: 24734219
Antioxidants (Basel). 2020 Feb 06;9(2):
pubmed: 32041293